Quanterix (QTRX) investor relations material

Leadership and strategic direction

• CEO brings 34 years of healthcare experience, focusing on expanding from research tools to clinical diagnostics, especially in Alzheimer's diagnostics.

• Diagnostics strategy centers on submitting a 510(k) for a multi-marker blood-based biomarker test, aiming for FDA approval in the second half of the year.

• Recent CFO transition brings in a leader with strong FP&A and integration experience, starting June 22.

• Emphasis on disciplined spending and pivoting from synergy realization to growth investments post-acquisition.

• Leadership additions include a diagnostics leader from Quest Diagnostics and returning Akoya talent to drive execution.

Diagnostics and clinical expansion

• LucentAD Complete, a five-marker test, reduces indeterminate results from 30% to 10% compared to single-marker tests.

• CMS priced the five-marker test at $897, significantly higher than single-marker alternatives, supporting margin expansion.

• Three clinical utility studies with major partners are expected to read out in the second half, supporting payer discussions.

• Multi-channel sales and marketing approach targets both neurology and primary care, leveraging partnerships like Tempus AI.

• HD-X instrument being upgraded for IVD readiness by 2027, supporting distributed and centralized diagnostic strategies.

Research tools and core business

• Research tools business remains robust, with a large install base and ongoing innovation (e.g., Simoa ONE in early access).

• Pharma and academia markets face broad-based headwinds, with deal sizes down but deal counts stable.

• NIH funding is up slightly, but spending hesitancy persists; company aims to be ready when funding releases.

• Upgrades to HD-X focus on reliability and workflow improvements to drive future placements.

• Productivity and cross-selling synergies from the Akoya acquisition are being realized, diversifying into oncology and immunology.